Acoustic speech markers for schizophrenia-spectrum disorders: a diagnostic and symptom-recognition tool

J. N. de Boer1,2, A. E. Voppel1, S. G. Brederoo1, H. G. Schnack2,3, K. P. Truong4, F. N. K. Wijnen3 and I. E. C. Sommer1

1Department of Biomedical Sciences of Cells and Systems and Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; 2Department of Psychiatry, University Medical Center Utrecht, Utrecht University & University Medical Center Utrecht Brain Center, Utrecht, the Netherlands; 3Utrecht Institute of Linguistics OTS, Utrecht University, Utrecht, the Netherlands and 4Department of Human Media Interaction, University of Twente, Enschede, the Netherlands

Abstract

Background. Clinicians routinely use impressions of speech as an element of mental status examination. In schizophrenia-spectrum disorders, descriptions of speech are used to assess the severity of psychotic symptoms. In the current study, we assessed the diagnostic value of acoustic speech parameters in schizophrenia-spectrum disorders, as well as its value in recognizing positive and negative symptoms.

Methods. Speech was obtained from 142 patients with a schizophrenia-spectrum disorder and 142 matched controls during a semi-structured interview on neutral topics. Patients were categorized as having predominantly positive or negative symptoms using the Positive and Negative Syndrome Scale (PANSS). Acoustic parameters were extracted with OpenSMILE, employing the extended Geneva Acoustic Minimalistic Parameter Set, which includes standardized analyses of pitch (F0), speech quality and pauses. Speech parameters were fed into a random forest algorithm with leave-ten-out cross-validation to assess their value for a schizophrenia-spectrum diagnosis, and PANSS subtype recognition.

Results. The machine-learning speech classifier attained an accuracy of 86.2% in classifying patients with a schizophrenia-spectrum disorder and controls on speech parameters alone. Patients with predominantly positive v. negative symptoms could be classified with an accuracy of 74.2%.

Conclusions. Our results show that automatically extracted speech parameters can be used to accurately classify patients with a schizophrenia-spectrum disorder and healthy controls, as well as differentiate between patients with predominantly positive v. negatives symptoms. Thus, the field of speech technology has provided a standardized, powerful tool that has high potential for clinical applications in diagnosis and differentiation, given its ease of comparison and replication across samples.

Introduction

In clinical practice, impressions of speech are routinely employed as an element of mental status examination and are a primary source of information in the diagnostic process. Especially in schizophrenia-spectrum disorders, descriptions of speech are used to assess specific symptoms such as alogia (e.g. poverty of speech) and blunted affect (e.g. diminished vocal intonation), as well as positive symptoms such as excitement (e.g. pressured speech; Alpert, Shaw, Pouget, & Lim, 2002). Although there is no consensus on the best sub-categorization of the different symptoms of schizophrenia-spectrum disorders yet, an important distinction is that between positive and negative symptoms. Being able to determine at different moments in time whether a schizophrenia-spectrum-patient experiences predominantly positive or negative symptoms is of great clinical importance because these symptom subtypes require different treatment (Fusar-Poli et al., 2015). Moreover, persistent negative symptoms are strongly related to functional outcomes (Lin et al., 2013; Milev, Ho, Arndt, & Andreasen, 2005), further highlighting the need for a reliable distinction between subtypes. From a scientific perspective, reliable identification of relevant subgroups of patients is highly important because the neuro-biological underpinnings of their disorders are likely different (Cuthbert & Insel, 2013; Insel, 2014). Consider a patient who presents with social withdrawal, alogia and catatonia: although both patients could be classified as having schizophrenia, the processes underlying these clinically non-overlapping symptom-collections might be entirely different.
Traditionally, clinical rating scales, such as the Positive and Negative Syndrome Scale (PANSS; Kay, Fiszbein, & Opfer, 1987) are used to assess both positive and negative symptoms in schizophrenia. However, previous research has stressed the dramatic disparity between speech-based objective measurements of individual characteristics (e.g. flat affect) and scale-based subjective assessments assessed by clinicians; symptom rating scales are, at best, only modestly related to objective measurements of the behavior they intend to reflect (Cohen, Mitchell, & Elvevåg, 2014). Moreover, some PANSS items are highly influenced by experience and preconceptions of the rater, which results in low inter-rater reliability (Kølbæk et al., 2018). In daily practice, these subjective assessments are not performed scale-based, but ad hoc, leading to even higher inter-observer variation. Especially, the assessment of negative symptoms remains problematic, since consensus-based instruments diverge on what should be considered true negative symptoms and what should be considered general/other illness components; such as, for example, cognition (Marder & Galderisi, 2017). Developing objective measurements to complement clinical ratings is thus fundamental to overcome these serious validity concerns with clinical assessments of positive and negative symptoms, and enable development towards measurement-based care (Insel, 2017).

Recent advances in natural language processing have paved the way towards automated speech analyses as a biomarker for psychosis (Corcoran et al., 2020; de Boer et al., 2018; de Boer, Brederoo, Voppel, & Sommer, 2020; Hitczenko, Mittal, & Goldrick, 2020; Tan & Rossell, 2020). Most studies in this field analyze language content, including methods of measuring discourse coherence, syntactic complexity and referential coherence (Bedi et al., 2015; Corcoran et al., 2018; Holmlund et al., 2020; Mota, Furtado, Maia, Copelli, & Ribeiro, 2014; Palaniyappan et al., 2019; Rezaii, Walker, & Wolff, 2019). A source of information that is less commonly used is the acoustic aspects of speech. Articulation and other components involved in speech production can be measured in the acoustic signal, for example by decomposing sound waves into formants; i.e. acoustic resonance frequencies that indicate the position and movement of the articulatory organs when speaking. F1 (first formant) indicates jaw/mouth opening and tongue height, while F2 corresponds to tongue positioning (front/back) and lip rounding. Furthermore, F0, or fundamental frequency, is an acoustic parameter of pitch. Such acoustic speech features (F0 and F2 variability) have been associated with specific negative symptoms (Bernardini et al., 2016; Covington et al., 2012) and have also been utilized as differentiators between individuals with schizophrenia-spectrum disorders and healthy individuals in small samples (Martinez-Sánchez et al., 2015; Tahir et al., 2019), attaining overall classification accuracies varying from 81% to 94%. Although these studies are promising, the larger literature also reports studies that failed to find a difference in acoustic features between schizophrenia-spectrum patients and healthy individuals (Cohen, Mitchell, Docherty, & Horan, 2016; Meaux, Mitchell, & Cohen, 2018).

These inconsistent findings may be due to the fact that several studies took different approaches to computing and standardizing acoustic parameters (Eyben et al., 2016). Individual research groups develop and employ their own set of features, and the studies reported above used acoustic feature sets that overlap only partially. Furthermore, studies often include non-acoustic features (e.g. the usage of determiners in speech) in their analyses. Therefore, the results reported in the literature cannot always be meaningfully compared (de Boer et al., 2020). Indeed, a recent meta-analysis found the existing literature to be highly diverse and unsystematic (Parola, Simonsen, Bliksted, & Fusaroli, 2020). Furthermore, the rapid developments in natural language processing have led to a proliferation in features, often amounting in up to tens of thousands of acoustic parameters (Marmar et al., 2019). While this abundance in features allows capturing many acoustic characteristics, it comes at the cost of overfitting and preventing clear interpretations of the underlying mechanisms (de Boer et al., 2020). We analyzed the speech of patients with a schizophrenia-spectrum disorder and healthy controls using the extended Geneva Acoustic Minimalistic Parameter Set (eGeMAPS) for acoustic analyses (Eyben et al., 2016). This parameter set was developed to provide a baseline for affective speech processing, in order to ensure easy replication and to improve comparability of parameters.

Overall, some recent studies have shown promising results in identifying schizophrenia-spectrum disorders from healthy controls utilizing automated analysis of acoustic speech patterns (Martinez-Sanchez et al., 2015; Tahir et al., 2019). Yet, inconsistencies remain and replications in large samples using interpretable and standardized speech parameters are required (Meaux et al., 2018; Parola et al., 2020). Thus, the first aim of the current study is to replicate the diagnostic potential of standardized speech parameters in a large sample of patients with a schizophrenia-spectrum disorder. The second aim is to explore the value of acoustic analyses in differentiating between patients who at that time experience predominantly positive vs. negative psychotic symptoms. Third, we aim to explore the relation between acoustic features and cognitive and psychotic symptoms, as well as the relation with antipsychotic medication. Based on previous study from our group, we specifically expect increased pauses to be related to the use of typical antipsychotics (de Boer, Voppel, Brederoo, Wijnen, & Sommer, 2020).

Methods

Participants

Data from 142 Dutch patients with a schizophrenia-spectrum disorder and 142 healthy age- and sex-matched controls from the same community were collected between 2015 and 2020. All procedures were approved by the Ethical Committee of the University Medical Center Utrecht. Psychiatric diagnoses were confirmed by the Structured Clinical Interview for DSM-IV (SCID; First, 2014), the Comprehensive Assessment of Symptoms and History (CASH; Andreasen, Flaum, & Arndt, 1992) or the Mini-International Interview (MINI; Sheehan et al., 1998), depending on the study the participants originally enrolled in. Healthy controls were screened for the absence of previous or current mental illness. Symptom severity and cognitive functioning were rated by consensus rating of two trained researchers, blinded to phonetic analysis, with the PANSS (Kay et al., 1987) and Brief Assessment of Cognition (BACS; Kefee et al., 2004). The patients were categorized as having predominant negative vs. positive symptoms based on PANSS scores. Since there is no consensus in the literature on cutoff scores for such subcategorizations, a median split was used. Patients were therefore categorized as having predominantly negative symptoms if they had a greater score on the negative than on the positive subscale of the PANSS, and a negative subscale score ≥ the median, being 12. The patients with predominantly positive symptoms consisted
of patients with PANSS positive subscale scores that were greater than their negative subscale scores, and a positive subscale score ≥ the median, being 9. Of the 142 schizophrenia-spectrum cases, 44 had predominantly positive symptoms and 45 had predominantly negative symptoms, the remaining patients had an equal combination of positive and negative symptoms.

Patients were divided into two categories based on different dopamine binding profiles, namely patients with (1) low dopamine D2 receptor (D2R) occupancy drugs (i.e. quetiapine, paliperidone, olanzapine and clozapine) or (2) high D2R occupancy drugs (i.e. aripiprazole, risperidone, flupentixol, amisulpride and haloperidol), following a previous report by our group (de Boer et al., 2020). Antipsychotic drug dosages were recalculated into chlorpromazine equivalents to evaluate the effect of dosage between the drugs (Leucht et al., 2014).

Procedure

Speech recording

Semi-structured interviews varying from 5 to 30 min in length (average 11 min) were conducted using a set of neutral open-ended questions. For an elaborate description of this methodology, see previous reports by our group (de Boer, van Hoogdalem, et al., 2020; de Boer, Voppel, et al., 2020; Voppel, de Boer, Breretroo, Schnack, & Sommer, 2021). AKG-C544i cardioid microphones were used to record the participant’s and interviewer’s speech onto two different channels. Speech was digitally recorded onto a Tascam DR40 solid state recorder, at a sampling rate of 44.1 kHz with 16-bit quantization. Head-worn microphones were used to keep the distance between the mouth and the microphone as constant as possible (2 cm), since this has a considerable effect on recorded vocal loudness. Microphones were placed at a 45° angle from the participant’s mouth in order to prevent aerodynamic noise.

Speech pre-processing

To remove crosstalk (i.e. speech from the interviewer on the participant’s audio channel), the following steps were taken: (1) the ‘annotate to text grid silences’ function in PRAAT (Boersma & Weenink, 2013) was used on the interviewer’s channel (settings: minimum pitch 100 Hz, time step 0.0, silence threshold −30.0 dB, minimum silence duration 1.0 s, minimum sounding duration 0.1 s); (2) all resulting speech segments in which the interviewer was silent were selected on the participants channel and (3) the resulting speech segments were concatenated into a new audio file containing only segments of speech of the participant.

Acoustic parameters

The eGeMAPS parameter set was extracted from the participant’s speech using OpenSMILE (Eyben, Weninger, Gross, & Schuller, 2013). eGeMAPS provides arithmetic means and coefficients of variation [standard deviation (s.d.) normalized by the arithmetic mean] for each parameter. A total of 88 parameters were computed at the speaker level and were used for feature selection and classification model building. For a full overview of the parameters, see online Supplementary Table S1. The parameters can be divided into the following types (Eyben et al., 2013): temporal (e.g. speech rate; six parameters), frequency (e.g. fundamental frequency; 24 parameters), spectral (e.g. Mel-frequency cepstral coefficients (MFCCs), relative energy in different frequency bands; 43 parameters) and energy/amplitude (e.g. intensity; 14 parameters).

Cognitive functioning

Cognition was assessed in all patients using the BACS (Keefe et al., 2004) which consists of the following tasks: (1) List learning – Verbal memory; (2) Digit sequencing - Working memory; (3) Token motor task - Motor speed; (4) Category Instances and Controlled Oral Word Association Test - Verbal fluency; (5) Symbol coding - Attention and information processing speed and (6) Tower of London - Executive function. Individual BACS scores were converted into standardized Z-scores that are corrected for age and gender based on previously published norm scores (Keefe et al., 2008).

Statistical analysis

For categorical variables, a $\chi^2$ test, and for continuous variables analysis of variance (ANOVAs) were used to assess differences between groups in demographic characteristics. Following previous research (Marmar et al., 2019), random forest algorithms were used to build machine-learning classifiers using acoustic speech parameters to differentiate between schizophrenia-spectrum patients and healthy controls, and to classify symptom patterns (i.e. predominantly positive v. predominantly negative symptoms). In this study, random forest classifiers were built using the 88 speech markers, using leave-ten-out cross-validation to divide the data into test and train sets. Random forests are based on multiple classification trees. The nodes in these decision trees are based on a binary ‘split’ of a predictor, aimed at minimizing misclassification in a training subset of the data. The process continues recursively until a tree is formed that does not improve from further splits or nodes. The probability of being a member of a certain target class, is the fraction of that class in the terminal node into which they fall. Once trees are iteratively built, per-case classification is performed on the testing subset. The resulting probability estimates are used to generate a receiver operator curve (ROC) and its area under the curve (AUC). From the trained trees, the importance of a specific predictor (Gini-importance score) is estimated by setting the predictor to a random number, and comparing the difference in predictive power (AUCs) to the final model, measuring how much worse the model becomes when replacing the predictor with random data. Gini-importance scores are average scores over all recursive trees, and can only be interpreted in relation to each other. Bivariate Pearson correlations were performed to analyze associations between acoustic variables and clinical characteristics in the patients for the top 10 features in both models. Correlation analyses were corrected for multiple comparison using false-discovery rate (FDR). Alpha was set to 0.05 for all analyses.

Results

The schizophrenia-spectrum patients and controls did not differ significantly in age, sex or parental educational levels (see Table 1). The patients overall received less education than the controls, which is to be expected given that the first psychosis often occurs during educational years. The schizophrenia-spectrum patients with predominantly positive symptoms had a longer illness duration than the patients with predominantly short illness duration.
Table 1. Demographics

|                          | HC (n = 142) | SSD (n = 142) | Predominantly positive symptoms (n = 44) | Predominantly negative symptoms (n = 45) | SSD v. HC | Predominantly positive v. negative symptoms | Statistic | p value | Statistic | p value |
|--------------------------|--------------|---------------|------------------------------------------|-------------------------------------------|-----------|---------------------------------------------|-----------|---------|-----------|---------|
| Sample size, n           | 142          | 142           | 44                                       | 45                                        | –         | –                                           | –         | –       | –         | –       |
| Male sex, n (%)          | 86 (60.6)    | 101 (71.1)    | 36 (81.8)                                | 32 (71.1)                                 | \(\chi^2 = 3.52\) | 0.061                                      | \(\chi^2 = 1.42\) | 0.234 |
| Age, mean years (S.D.)   | 34.5 (13.75) | 32.4 (12.53)  | 34.5 (13.03)                             | 26.7 (9.95)                               | \(F = 1.65\) | 0.200                                      | \(F = 3.84\) | 0.053 |
| Years of education, mean (S.D.) | 15.0 (1.77) | 13.2 (2.38)  | 12.9 (2.63)                              | 13.4 (13.44)                             | \(F = 51.4\) | <0.001**                                   | \(F = .987\) | 0.323 |
| Duration disease years, mean (S.D.) | –          | 6.4 (10.26)  | 9.5 (12.35)                              | 3.2 (6.76)                               | \(F = 1.13\) | 0.288                                      | \(F = .671\) | 0.415 |
| Chlorpromazine equivalent, mean (S.D.) | –          | 237.0 (154.53) | 268.5 (173.67) | 228.7 (136.58) | \(F = 1.31\) | 0.257                                      | \(F = 9.00\) | 0.004** |
| DSM diagnosis, n (%)     | –            | 55 (38.7)     | 19 (43.2)                                | 21 (46.7)                                | \(\chi^2 = 3.89\) | 0.506                                      | \(\chi^2 = 3.89\) | 0.506 |
| Schizophrenia            | –            | 7 (4.9)       | 2 (4.5)                                  | 2 (4.4)                                  | –         | –                                           | –         | –       | –         | –       |
| Schizophreniform disorder| –            | 7 (4.9)       | 2 (4.5)                                  | 2 (4.4)                                  | –         | –                                           | –         | –       | –         | –       |
| Schizoaffective disorder | –            | 15 (10.6)     | 6 (13.6)                                 | 2 (4.4)                                  | –         | –                                           | –         | –       | –         | –       |
| Psychosis NOS            | –            | 65 (45.8)     | 17 (38.6)                                | 20 (44.4)                                | –         | –                                           | –         | –       | –         | –       |
| PANSS, mean (S.D.)       | –            | 47.0 (15.30)  | 51.3 (12.36)                             | 55.2 (9.61)                              | \(F = 2.65\) | 0.107                                      | \(F = 32.5\) | <0.001** |
| Total                    | –            | 10.5 (4.70)   | 14.7 (4.45)                              | 10.2 (2.80)                              | \(F = 80.3\) | <0.001**                                   | \(F = 1.07\) | 0.303 |
| Positive                 | –            | 12.3 (5.35)   | 10.7 (3.36)                              | 17.6 (3.88)                              | \(F = 80.3\) | <0.001**                                   | \(F = 1.07\) | 0.303 |
| Negative                 | –            | 24.2 (7.94)   | 26.0 (6.53)                              | 27.4 (6.21)                              | \(F = 80.3\) | <0.001**                                   | \(F = 1.07\) | 0.303 |

HC: healthy controls; SSD: schizophrenia-spectrum disorder patients.

Psychotic symptom subgroup analyses were performed in those patients that met criteria for either predominantly positive or negative symptoms. These subgroups are a subset (n = 89) of the full schizophrenia-spectrum disorder sample (n = 142).

** Indicates p value <0.01.
negative symptoms. These subgroups did not differ significantly on age, sex and parental educational levels. The patients with predominantly positive symptoms had a longer illness duration than the patients with predominantly negative symptoms (Table 1).

**Diagnostic classifier**

The trained 10-fold cross-validated classifier had an accuracy of 86.2% with an AUC of 0.92 in distinguishing schizophrenia-spectrum patients from healthy controls. Sensitivity was 83.1% and specificity 87.2% (see Table 2).

Table 3 lists the ten acoustic parameters with the highest importance scores in the final model, as well as the means and S.D.s of these parameters in the schizophrenia-spectrum patients and controls. For a full list of Gini-importance scores, see online Supplementary Table S1. Three of the top parameters in the model were temporal (voiced segment rate, unvoiced segment length and S.D.), indicating short, fragmented speech segments and longer pauses in the schizophrenia-spectrum patients compared to controls. Patients with a schizophrenia-spectrum disorder were further classified using spectral parameters between groups, namely a reduced mean spectral slope of voiced and unvoiced regions (indicating a more tensed voice in the patients) and reduced spectral flux variation (i.e. less difference between spectra measured between two consecutive time windows, which may indicate more monotone speech). Patients were further characterized by reduced variation of F2 bandwidth (i.e. vocal fold bandwidth, can indicate breathiness). Moreover, the energy of the first and third formant as compared to pitch (F0) differed from healthy controls, indicating differences in intonation characteristics and voice quality. The patients showed a larger variation in loudness compared to the controls.

**Psychotic symptoms classifier**

The trained 10-fold cross-validated model had an accuracy of 74.2% with an AUC-ROC of 0.76 in distinguishing patients with predominantly negative from those with predominantly positive symptoms. Sensitivity was 65.9% and specificity 80.0% (see Table 2). Table 4 lists the top ten acoustic parameters in the trained model, as well as the means and S.D.s of these parameters in the predominant positive and negative symptom groups. For a full list of Gini-importance scores, see online Supplementary Table S2. Patients with positive symptoms had a smaller spectral slope indicating a smaller difference in energy between low and high frequencies. Other spectral parameters did not differ between groups. Seven of the top ten parameters were frequency parameters (i.e. relating to the way vowels are pronounced); patients with positive symptoms had a smaller F1 and F2 bandwidth (i.e. vowel bandwidth, indicating breathiness), lower mean F1 frequencies, less jitter variation (i.e. roughness or voice quality) and less variation in F3 frequency (i.e. vowel frequency).

**Associations between acoustic variables and clinical characteristics**

**Psychotic and cognitive symptoms**

Pearson correlations for the top ten parameters from both classifiers with PANSS positive, negative and general composite BACS scores are presented in Table 5. Acoustic variables correlated most strongly with negative and to a lesser degree general PANSS scores. After FDR correction, no significant associations with cognitive functioning were found.

**Antipsychotic medication**

Pearson correlations between chlorpromazine equivalents and all 88 acoustic parameters revealed only one weak association; slope V500–1500 (S.D.) was correlated with chlorpromazine equivalent dose ($r = -0.207$, $p = 0.019$). This association did not remain significant after FDR correction. A multivariate analysis of variance (MANOVA) analysis comparing patients with low DR2 occupancy drugs with patients using high DR2 occupancy drugs, and chlorpromazine equivalent dose as a covariate, revealed no significant overall group effect of medication type ($F_{(1, 85)} = 1.191, p = 0.269$) or dose ($F_{(1, 85)} = 1.260, p = 0.206$) on the acoustic parameters. An ANOVA analysis comparing the two medication groups on pause duration (mean unvoiced segment length) specifically, with chlorpromazine equivalent dose as a covariate, revealed a significant main effect of drug type ($F_{(1, 126)} = 4.532, p = 0.035$, partial $R^2 = 0.035$). Antipsychotic dose showed no significant effect on pause duration ($p = 0.642$). Patients with high DR2 occupancy drugs showed a greater pause duration (mean = 0.28) than the patients with low DR2 occupancy drugs (mean = 0.24).

**Discussion**

This study confirms previous research in showing that patients with a schizophrenia-spectrum disorder can be reliably distinguished from healthy control participants by using automated speech-based techniques, in a large sample. We extend the current literature by further showing that patients with a schizophrenia-spectrum disorder can be divided into those with predominantly positive vs. negative symptoms based on their speech acoustics. By using standardized acoustic measures, high sensitivity, specificity and accuracy could be achieved in differentiating patients from controls. The model assigns higher probability to a schizophrenia-spectrum diagnosis when speech is fragmented (i.e. frequent short-speech segments), has a decreased spectral slope (i.e. less difference in energy between high- and low-speech
| Ranking | Parameter                          | Description                                                                 | May reflect                | Feature type | Mean HC (S.D.) | Mean SZ (S.D.) | F-statistic | p value     |
|---------|-----------------------------------|-----------------------------------------------------------------------------|---------------------------|--------------|---------------|---------------|-------------|-------------|
| 1       | Voiced segments per second (mean) | Average number of continuous voiced regions per second (more segments indicates more fragmented speech with short speech segments). | Fragmentedness of speech  | Temporal     | 1.25 (0.014)  | 1.75 (0.559)  | 103.3       | <0.001**    |
| 2       | Slope UV 500–1500 (mean)          | Mean spectral Slope 0–500 Hz and 500–1500 Hz of unvoiced regions; linear regression slope of the logarithmic power spectrum within the two given bands. | Tension                   | Spectral     | −0.009 (0.0024) | −0.006 (0.0025) | 75.1        | <0.001**    |
| 3       | F2 bandwidth (s.d.)               | S.D. of the bandwidth of second formant                                     | Breathiness               | Frequency    | 0.36 (0.004)  | 0.33 (0.047)  | 20.0        | <0.001**    |
| 4       | Unvoiced segment length (mean)    | The mean length of unvoiced regions (F0 = 0; approximating pauses).         | Pause length              | Temporal     | 0.20 (0.006)  | 0.26 (0.108)  | 33.9        | <0.001**    |
| 5       | Spectral flux (s.d.)              | S.D. of spectral flux difference of the spectra of two consecutive frames.  | Monotone speech           | Spectral     | 1.26 (0.178)  | 1.38 (0.241)  | 20.3        | <0.001**    |
| 6       | Loudness (s.d.)                   | Loudness; estimate of perceived signal intensity from an auditory spectrum. | Loudness                  | Energy/amplitude | 0.96 (0.119) | 1.06 (0.161)  | 33.7        | <0.001**    |
| 7       | Slope V 500–1500 (mean)           | Mean spectral Slope 0–500 Hz and 500–1500 Hz of voiced regions; linear regression slope of the logarithmic power spectrum within the two given bands. | Tension                   | Spectral     | −0.02 (0.003) | −0.02 (0.003) | 26.8        | <0.001**    |
| 8       | F3 log relative amplitude (s.d.)  | S.D. of relative energy of the third formant’s center frequency to the energy of the spectral peak at F0. | Vowel pronunciation       | Spectral     | −0.73 (0.071) | −0.68 (0.093) | 27.2        | <0.001**    |
| 9       | F1 log relative amplitude (mean)  | Mean relative energy of the first formant’s center frequency to the energy of the spectral peak at F0. | Vowel pronunciation       | Spectral     | −96.3 (14.29) | −105.7 (17.96) | 23.6        | <0.001**    |
| 10      | Unvoiced segment length (s.d.)    | S.D. of unvoiced regions (F0 = 0; approximating pauses).                    | Pause length              | Temporal     | 0.39 (0.140)  | 0.50 (0.243)  | 75.1        | <0.001**    |

s.d., standard deviation; UV, unvoiced; V, voiced.

Ranking based on average Gini-importance scores.

** indicates p value <0.01.
| Ranking | Parameter | Description | May reflect | Feature type | Mean predominantly positive patients (s.d.) | Mean predominantly negative patients (s.d.) | F-statistic | p value |
|---------|-----------|-------------|-------------|--------------|---------------------------------------------|---------------------------------------------|-------------|---------|
| 1       | Slope UV 500–1500 (mean) | Mean spectral slope 0–500 Hz and 500–1500 Hz of unvoiced regions; linear regression slope of the logarithmic power spectrum within the two given bands. | Tension | Spectral | −0.03 (0.012) | −0.04 (0.017) | 10.6 | 0.002** |
| 2       | MFCC3 (s.d.) | s.d. of Mel-Frequency Cepstral Coefficient 3. | Timbre | Spectral | 0.70 (0.149) | 0.68 (0.218) | 0.824 | 0.366 |
| 3       | F1 bandwidth (mean) | Mean bandwidth of first formant. | Breathiness | Frequency | 1283.7 (54.01) | 1318.0 (43.78) | 10.9 | 0.001** |
| 4       | F3 frequency (s.d.) | s.d. of third formant frequency. | Vowel pronunciation | Frequency | 0.11 (0.017) | 0.12 (0.012) | 4.15 | 0.045* |
| 5       | Jitter (s.d.) | s.d. of jitter; deviations in individual consecutive F0 period lengths. | Voice quality | Frequency | 1.77 (0.240) | 1.88 (0.255) | 4.7 | 0.034* |
| 6       | F2 bandwidth (mean) | Mean bandwidth of second formant. | Breathiness | Frequency | 995.9 (76.23) | 1034.9 (58.34) | 7.37 | 0.008** |
| 7       | F1 frequency (mean) | Mean frequency of first formant. | Vowel pronunciation | Frequency | 511.0 (58.91) | 521.3 (41.84) | 0.949 | 0.333 |
| 8       | Alpha ratio voiced (s.d.) | s.d. of the alpha ratio of voiced segments; ratio of the summed energy from 50 Hz to 1000 Hz and 1–5 kHz | Voice quality | Spectral | −0.36 (0.031) | −0.35 (0.043) | 1.45 | 0.232 |
| 9       | F2 frequency (s.d.) | s.d. of second formant frequency. | Vowel pronunciation | Frequency | 1507.5 (78.60) | 1528.4 (68.55) | 2.97 | 0.089 |
| 10      | F3 bandwidth (mean) | Mean bandwidth of third formant. | Breathiness | Frequency | 866.0 (84.45) | 907.4 (66.85) | 6.59 | 0.012* |

Ranking based on average Gini-importance scores. s.d.: standard deviation; UV: unvoiced; V: voiced. ** indicates p value <0.01, * indicates p value <0.05.
frequencies) and longer pauses. We further demonstrated that speech parameters can be used to identify subjects with positive and negative symptoms in schizophrenia-spectrum disorders. This model assigns higher probability to positive symptoms and negative symptoms in schizophrenia-spectrum disorders.

Our results revealed no effect of antipsychotic medication dose on the acoustic parameters, which is in accordance with our previous work (de Boer et al., 2020). Furthermore, although we did not find an overall effect of drug type on the acoustic variables, we replicated our previous work in showing that the use of high DR2 drugs was associated with increased pausing (de Boer et al., 2020).

Table 5. Associations between top acoustic parameters and psychotic and cognitive symptoms

| Classifier and ranking | Acoustic parameters                        | PANSS Positive       | PANSS Negative       | PANSS General         | BACS composite |
|------------------------|--------------------------------------------|----------------------|----------------------|-----------------------|----------------|
| Diagnostic 1           | Voiced segments per second (mean)          | −0.299**             | 0.005                | −0.170*               | −0.113         |
| Diagnostic 2           | Slope UV 500–1500 (mean)                  | −0.003               | −0.087               | 0.031                 | 0.063          |
| Diagnostic 3           | F2 bandwidth (s.o.)                        | −0.087               | −0.160               | −0.113                | −0.041         |
| Diagnostic 4           | Unvoiced segment length (mean)             | 0.096                | 0.163                | 0.143                 | −0.017         |
| Diagnostic 5           | Spectral flux (s.o.)                       | 0.087                | 0.250**              | 0.187*                | −0.058         |
| Diagnostic 6           | Loudness (s.o.)                            | 0.050                | 0.264**              | 0.193*                | −0.093         |
| Diagnostic 7           | Slope V 500–1500 (mean)                   | 0.096                | 0.109                | 0.077                 | −0.007         |
| Diagnostic 8           | F3 log relative amplitude (s.o.)           | 0.111                | 0.351**              | 0.271**               | −0.132         |
| Diagnostic 9           | F1 log relative amplitude (mean)           | −0.095               | −0.298**             | −0.226**              | 0.125          |
| Diagnostic 10          | Unvoiced segment length (s.o.)             | 0.106                | 0.094                | 0.105                 | 0.017          |
| Symptoms 1             | Slope UV 500–1500 (mean)                  | −0.003               | −0.087               | 0.031                 | 0.063          |
| Symptoms 2             | MFCC3 (s.o.)                              | −0.004               | −0.114               | −0.067                | 0.006          |
| Symptoms 3             | F1 bandwidth (mean)                        | −0.063               | 0.261**              | 0.180*                | −0.074         |
| Symptoms 4             | F3 frequency (s.o.)                        | 0.010                | 0.201*               | 0.153                 | 0.033          |
| Symptoms 5             | Jitter (s.o.)                              | −0.098               | 0.047                | −0.018                | −0.115         |
| Symptoms 6             | F2 bandwidth (mean)                        | 0.012                | 0.284**              | 0.205*                | −0.017         |
| Symptoms 7             | F1 frequency (mean)                        | −0.102               | 0.021                | 0.007                 | −0.180*        |
| Symptoms 8             | Alpha ratio voiced (s.o.)                  | 0.079                | 0.248**              | 0.297**               | −0.107         |
| Symptoms 9             | F2 frequency (s.o.)                        | −0.042               | 0.097                | 0.140                 | 0.004          |
| Symptoms 10            | F3 bandwidth (mean)                        | 0.054                | 0.271**              | 0.171*                | 0.024          |

Legend: Reported values are Pearson’s r values. ** indicates p value <0.01, * indicates p value <0.05. Bold values remained significant after FDR correction for multiple comparisons.
individual person. Further longitudinal studies are required to ascertain how speech disturbances in schizophrenia-spectrum disorders develop over time (Arevian et al., 2020; Cohen et al., 2019).

There were a number of limitations in the study. First, although conservative leave-ten-out cross-validation was employed, there remains a risk of overfitting. Replication in an independent dataset is therefore required. Secondly, although several variables that can influence the results have been explored, not all factors could be controlled for. For example, we had no data on smoking behavior, length or weight, which are known to influence some aspects of speech. Moreover, the recordings were made in different rooms, which may have affected some of the acoustic aspects of speech. Therefore, future research should assess the specificity of the classifier by controlling for these factors and by testing its performance in differential diagnosis of psychiatric disorders. Finally, it should be noted that we averaged the acoustic parameters over the interview duration (mean duration 10.8 min), which precludes dynamic differences over time. Further research should therefore also incorporate dynamic aspects of speech acoustics, such as convergence between speech patterns, to fully acknowledge the within-subject variety of speech acoustics as well.

In conclusion, these findings show that standardized acoustic speech parameters can be used to accurately classify patients with a schizophrenia-spectrum disorder and healthy controls, as well as differentiate between patients with predominantly positive and negative symptoms. Our findings support the usefulness of computational tools to characterize complex human behavior such as speech. We strongly encourage the use of standardized open-source software packages such as eGeMAPS since they ensure easy comparison and replication across samples and even cross-linguistically.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291721002804.

Data. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available as they contain information that could compromise research participant privacy or consent.

Acknowledgements. We are grateful to all participants and research interns for their help with data collection and preparation.

Author contributions. Janna de Boer: conceptualization, Methodology, Formal analysis, Investigation, Writing – Original draft. Alban Voppel: Methodology, Software, Investigation. Sanne Brederoo: Writing – Review and Editing. Hugo Schnack: Writing – Review & Editing, Supervision. khiet Truong: Writing - Review & Editing, Supervision, Frank Wijnen: Writing - Review & Editing, Supervision. Iris Sommer: Writing - Review & Editing, Supervision, Funding acquisition

Financial support. I. S. received a TOP grant from The Netherlands Organization for Health Research and Innovation (ZonMW, project: 91213009).

Conflict of interest. I. S. is a consultant to Gabather, received research support from Janssen Pharmaceuticals Inc. and Sunovion Pharmaceuticals Inc.

References
Alpert, M., Pouget, E. R., & Silva, R. (1995). Cues to the assessment of affects and moods: Speech fluency and pausing. Psychopharmacology Bulletin, 31 (2), 421–424.
Alpert, M., Shaw, R. J., Pouget, E. R., & Lim, K. O. (2002). A comparison of clinical ratings with vocal acoustic measures of flat affect and alogia. Journal of Psychiatric Research, 36(5), 347–353.
Meaux, L. T., Mitchell, K. R., & Cohen, A. S. (2018). Blunted vocal affect and expression is not associated with schizophrenia: A computerized acoustic analysis of speech under ambiguous conditions. *Comprehensive Psychiatry, 83*, 84–88. doi: 10.1016/j.comppsych.2018.03.009

Milev, P., Ho, B.-C., Arndt, S., & Andreasen, N. C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. *American Journal of Psychiatry, 162*(3), 495–506.

Mota, N. B., Furtado, R., Maia, P. P. C., Copelli, M., & Ribeiro, S. (2014). Graph analysis of dream reports is especially informative about psychosis. *Scientific Reports, 4*, 3691.

Nolan, F., & Grigoras, C. (2005). A case for formant analysis in forensic speaker identification. *International Journal of Speech, Language and the Law, 12*(2), 143–173.

Oomen, P., de Boer, J. N., Brederoo, S. G., Voppel, A. E., Brand, B. A., Wijnen, F. N. K., … Sommer, I. E. C. (2021). Characterizing speech heterogeneity in schizophrenia-spectrum disorders. *Journal of Abnormal Psychology*, In press.

Palaniyappan, L., Mota, N. B., Oowise, S., Balain, V., Copelli, M., Ribeiro, S., & Liddle, P. F. (2019). Speech structure links the neural and socio-behavioural correlates of psychotic disorders. *Progress in Neuro-Psychopharmacology and Biological Psychiatry, 88*(April 2018), 112–120. doi: 10.1016/j.pnpbp.2018.07.007

Parola, A., Simonsen, A., Bliksted, V., & Fusaroli, R. (2020). Voice patterns in schizophrenia: A systematic review and Bayesian meta-analysis. *Schizophrenia Research, 216*, 24–40. doi: 10.1093/schbul/sby164.414

Rezaii, N., Walker, E., & Wolff, P. (2019). A machine learning approach to predicting psychosis using semantic density and latent content analysis. *npj Schizophrenia, 5*(1), 1–12.

Schnack, H. (2020). Bias, noise, and interpretability in machine learning: From measurements to features. In A. Mechelli & S. Vieira (Eds.), *Machine learning: Methods and applications to brain disorders* (pp. 307–328). Cambridge, Massachusetts: Elsevier.

Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., … Dunbar, G. C. (1998). The mini-international neuropsychiatric interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry, 59*(Suppl 20), 22–33.

Simantiraki, O., Giannakakis, G., Pampouchidou, A., & Tsiknakis, M. (2016). Stress Detection from Speech Using Spectral Slope Measurements. *Starkie, G., De Clercq, E., Borgwardt, S., & Elger, B. S. (2020). Computing schizophrenia: Ethical challenges for machine learning in psychiatry. Psychological Medicine, 1–7."

Tahir, Y., Yang, Z., Chakraborty, D., Thalman, N., Thalman, D., Maniam, Y., … Dauwels, J. (2019). Non-verbal speech cues as objective measures for negative symptoms in patients with schizophrenia. *PLoS One, 14*(4), 1–17.

Tan, E. J., & Rossell, S. L. (2020). Questioning the status of aberrant speech patterns as psychiatric symptoms. *The British Journal of Psychiatry, 217*(3), 469–470.

Voppel, A., de Boer, J., Brederoo, S., Schnack, H., & Sommer, I. (2021). Quantified language connectedness in schizophrenia-spectrum disorders. *Psychiatry Research, 304*, 114130.